Lamivudine Patent Expiration
Lamivudine is Used for treating hepatitis B infection. It was first introduced by Viiv Healthcare Co
Lamivudine Patents
Given below is the list of patents protecting Lamivudine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Epivir |
US6004968 (Pediatric) | Pharmaceutical compositions containing lamivudine |
Sep 20, 2018
(Expired) | Viiv Hlthcare |
| Epivir-hbv |
US6004968 (Pediatric) | Pharmaceutical compositions containing lamivudine |
Sep 20, 2018
(Expired) | Glaxosmithkline |
| Epivir | US6004968 | Pharmaceutical compositions containing lamivudine |
Mar 20, 2018
(Expired) | Viiv Hlthcare |
| Epivir-hbv | US6004968 | Pharmaceutical compositions containing lamivudine |
Mar 20, 2018
(Expired) | Glaxosmithkline |
| Epivir |
US5905082 (Pediatric) | Crystalline oxathiolane derivatives |
Nov 18, 2016
(Expired) | Viiv Hlthcare |
| Epivir-hbv |
US5905082 (Pediatric) | Crystalline oxathiolane derivatives |
Nov 18, 2016
(Expired) | Glaxosmithkline |
| Epivir | US5905082 | Crystalline oxathiolane derivatives |
May 18, 2016
(Expired) | Viiv Hlthcare |
| Epivir | US5905082 | Crystalline oxathiolane derivatives |
May 18, 2016
(Expired) | Viiv Hlthcare |
| Epivir-hbv | US5905082 | Crystalline oxathiolane derivatives |
May 18, 2016
(Expired) | Glaxosmithkline |
| Epivir-hbv |
USRE39155 (Pediatric) | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jan 02, 2014
(Expired) | Glaxosmithkline |
| Epivir-hbv | USRE39155 | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jul 02, 2013
(Expired) | Glaxosmithkline |
Lamivudine's Family Patents
Explore Our Curated Drug Screens
Lamivudine Generic API Manufacturers
Several generic applications have been filed for Lamivudine. The first generic version for Lamivudine was by Aurobindo Pharma Ltd and was approved on Nov 17, 2011. And the latest generic version is by Hetero Labs Ltd Unit Iii and was approved on Oct 6, 2023.
Given below is the list of companies who have filed for Lamivudine generic, along with the locations of their manufacturing plants worldwide.
1. ANNORA
Annora Pharma Private Ltd has filed for 1 generic for Lamivudine. Given below are the details of the strengths of this generic introduced by Annora.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet | Prescription | ORAL | AB | Mar 21, 2019 |
Manufacturing Plant Locations New
Annora's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Annora as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
2. APOTEX
Apotex Inc has filed for 3 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Dec 2, 2011 |
| 300MG | tablet | Prescription | ORAL | AB | Dec 2, 2011 |
| 100MG
(reference standard) | tablet | Prescription | ORAL | AB | Jan 2, 2014 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
3. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 3 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Nov 21, 2016 |
| 150MG | tablet | Prescription | ORAL | AB | Nov 21, 2016 |
| 10MG/ML | solution | Prescription | ORAL | AA | Nov 21, 2016 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
| United States |
| |||||||||
4. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Discontinued | ORAL | N/A | Nov 17, 2011 |
| 300MG | tablet | Discontinued | ORAL | N/A | Nov 17, 2011 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
5. AUROBINDO PHARMA USA
Aurobindo Pharma Usa Inc has filed for 1 generic for Lamivudine. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet | Discontinued | ORAL | N/A | Dec 31, 2014 |
Manufacturing Plant Locations New
Aurobindo Pharma Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Usa as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
6. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 1 generic for Lamivudine. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Nov 21, 2016 |
Manufacturing Plant Locations New
Breckenridge's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Breckenridge as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
7. CHARTWELL MOLECULAR
Chartwell Molecular Holdings Llc has filed for 1 generic for Lamivudine. Given below are the details of the strengths of this generic introduced by Chartwell Molecular.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG/ML | solution | Prescription | ORAL | AA | Oct 31, 2014 |
8. CIPLA
Cipla Ltd has filed for 2 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Mar 3, 2017 |
| 300MG | tablet | Prescription | ORAL | AB | Mar 3, 2017 |
Manufacturing Plant Locations New
Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
9. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 1 generic for Lamivudine. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG/ML | solution | Prescription | ORAL | AA | Oct 6, 2023 |
10. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 3 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet | Prescription | ORAL | AB | Jan 2, 2014 |
| 150MG | tablet | Prescription | ORAL | AB | Jan 6, 2014 |
| 300MG | tablet | Prescription | ORAL | AB | Jan 6, 2014 |
11. LUPIN LTD
Lupin Ltd has filed for 2 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Dec 18, 2014 |
| 300MG | tablet | Prescription | ORAL | AB | Dec 18, 2014 |
Manufacturing Plant Locations New
Lupin Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Lupin Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
12. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | May 1, 2019 |
| 300MG | tablet | Prescription | ORAL | AB | May 1, 2019 |
13. MYLAN LABS LTD
Mylan Laboratories Ltd has filed for 2 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Mylan Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Discontinued | ORAL | N/A | Mar 5, 2019 |
| 150MG | tablet | Discontinued | ORAL | N/A | Mar 5, 2019 |
14. NATCO
Natco Pharma Ltd has filed for 2 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Natco.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Discontinued | ORAL | N/A | Mar 4, 2016 |
| 300MG | tablet | Discontinued | ORAL | N/A | Mar 4, 2016 |
Manufacturing Plant Locations New
Natco's manufacturing plants are situated in 2 countries - United Kingdom, India. Given below are the details of these plant locations as well as the firm names of Natco as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom |
| |||||||||||||
| India |
| |||||||||||||
15. STRIDES PHARMA
Strides Pharma Global Pte Ltd has filed for 2 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Strides Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Apr 19, 2018 |
| 150MG | tablet | Prescription | ORAL | AB | Apr 19, 2018 |
Manufacturing Plant Locations New
Strides Pharma's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Strides Pharma as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| India |
| |||||
16. UPSHER SMITH LABS
Upsher Smith Laboratories Llc has filed for 2 different strengths of generic version for Lamivudine. Given below are the details of the strengths of this generic introduced by Upsher Smith Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Nov 21, 2016 |
| 300MG | tablet | Prescription | ORAL | AB | Nov 21, 2016 |